

**Short Communication**DOI: <https://doi.org/10.47275/2692-093X-149>  
Volume 7 Issue 1

# Gene Therapy for Parkinson's Disease: Evaluating Current Platforms and Clinical Outcomes

Ashmit Gupta<sup>1</sup>, Sree Hasa Prudhvi Pemmasani<sup>2\*</sup>, Harshitha Tallapally<sup>3</sup> and Sowthrishta Paluri<sup>4\*</sup><sup>1</sup>SBKS Medical College and Research Centre, Vadodara, Gujarat, India<sup>2</sup>PSG Institute of Medical Sciences and Research, Coimbatore, Tamil Nadu, India<sup>3</sup>Osmania Medical College, Hyderabad, Telangana, India<sup>4</sup>G.S.L Medical College, Rajahmundry, Andhra Pradesh, India

## Abstract

Parkinson's disease management remains heavily reliant on symptomatic treatments, which often lead to debilitating complications over time, creating a pressing need for interventions that offer durable benefits and potentially modify disease progression. While gene therapy has emerged as a promising strategy to address this unmet need, its clinical translation has been marked by both encouraging advances and significant setbacks. This paper therefore aims to critically evaluate the current landscape of gene therapy for Parkinson's disease, synthesizing evidence on its platforms, clinical outcomes, and persistent challenges. This paper comprehensively examines molecular strategies that extend beyond dopamine replacement, including enhanced dopamine synthesis, neurotrophic support, and neural circuit modulation. It analyzes the viral vector platforms that enable these therapies, with a focus on adeno-associated virus and lentivirus (LV) and underscores the critical role of convection-enhanced delivery for achieving adequate distribution in the human brain. Furthermore, the paper delves into the designs and endpoint challenges of pivotal clinical trials, synthesizes the available safety and immunogenicity data, and discusses the impact of surgical delivery precision on therapeutic efficacy. Looking forward, the future of gene therapy for Parkinson's disease hinges on overcoming key hurdles in vector design, immune response modulation, and biomarker development. Success will depend on refining delivery techniques to ensure consistent target coverage and designing trials capable of definitively demonstrating disease-modifying effects. As these innovative platforms continue to evolve, they hold the potential to fundamentally transform the therapeutic paradigm for Parkinson's disease, moving from symptomatic management to long-term disease modification.

**Keywords:** Adeno-associated virus, Convection-enhanced delivery, Gene therapy, Lentivirus, Neurotrophic factors, Parkinson's disease, Surgical delivery, Viral vectors

\***Correspondence to:** Sree Hasa Prudhvi Pemmasani and Sowthrishta Paluri, PSG Institute of Medical Sciences and Research, Coimbatore, Tamil Nadu, India and G.S.L Medical College, Rajahmundry, Andhra Pradesh, India.

**Citation:** Gupta A, Pemmasani SHP, Tallapally H, Paluri S (2026) Gene Therapy for Parkinson's Disease: Evaluating Current Platforms and Clinical Outcomes. *Neurol Sci Neurosurg*, Volume 7:1. 149. DOI: <https://doi.org/10.47275/2692-093X-149>

**Received:** April 14, 2026; **Accepted:** July 06, 2026; **Published:** July 10, 2026

## Introduction

A comprehensive evaluation of gene therapy platforms and clinical outcomes in Parkinson's disease reveals a rapidly evolving landscape, with promising approaches rooted in molecular and genetic interventions [1-4]. The current state of gene therapy for Parkinson's disease is characterized by strategies aimed at restoring dopaminergic function, modifying disease progression, and improving patient quality of life, although challenges remain in translating these approaches into consistent clinical benefits [5-8].

One of the primary rationales for gene therapy in Parkinson's disease involves augmenting dopamine synthesis within affected neural circuits. Feng and Maguire-Zeiss [9] provide an overview of ongoing clinical trials that focus on increasing dopamine production through direct delivery of genes involved in neurotransmitter synthesis, such as amino acid decarboxylase, tyrosine hydroxylase, and guanosine triphosphate cyclohydrolase 1. These approaches aim to compensate for the loss of dopaminergic neurons characteristic of Parkinson's disease, with the goal of alleviating motor symptoms. The rationale is supported by the understanding that targeted gene delivery can potentially restore

neurotransmitter balance, thereby improving motor function.

In addition to neurotransmitter synthesis, gene therapy strategies are exploring neuroprotective and disease-modifying avenues. O'Connor and Boulis [10] discuss the broader scope of gene therapy for neurodegenerative diseases, emphasizing the importance of targeting pathogenic mechanisms and delivering therapeutic genes that can modify disease progression. Despite these promising concepts, recent clinical trials testing various gene therapy modalities, including adeno-associated viral (AAV) vectors-mediated delivery of neurotrophic factors like neurturin (NRTN), have not yet demonstrated definitive efficacy [11]. This highlights the complexity of Parkinson's disease pathology and the need for refined delivery methods and target selection.

The delivery of genetic material remains a critical challenge in Parkinson's disease gene therapy. Abignano et al. [12] underscore the importance of biomarkers and innovative approaches such as gene expression analysis to monitor disease activity and therapeutic response. The development of reliable biomarkers is essential for assessing the efficacy of gene therapy interventions and for tailoring



personalized treatment strategies. Similarly, Deverman et al. [13] reviewed advances in vector design, particularly adeno-associated virus vectors, which are increasingly used due to their safety and ability to sustain transgene expression in neural tissues. These vectors are central to current clinical trials, with ongoing efforts to optimize their targeting, transduction efficiency, and immune evasion.

Preclinical studies provide further insights into the potential of gene therapy for Parkinson's disease. Rhee et al. [14] demonstrate that human induced pluripotent stem cell derived dopamine neurons can be transplanted into rat models of Parkinson's disease, resulting in significant motor recovery. This approach complements gene therapy by offering regenerative potential, although translating these findings into human clinical trials requires overcoming immunogenicity and ensuring long-term safety. Kefalopoulou et al. [15] report long-term outcomes of fetal cell transplantation, which, although not gene therapy per se, inform on the durability and safety of cell-based interventions, providing valuable context for gene-based regenerative strategies.

The clinical translation of gene therapy for Parkinson's disease also involves evaluating long-term safety and efficacy. Kefalopoulou et al. [15] present case reports indicating sustained benefits from fetal cell transplantation, which may inform future gene therapy trials aiming for similar durable effects. However, the variability in clinical outcomes underscores the necessity for standardized endpoints and rigorous trial designs. Corbacioglu et al. [16] emphasize the importance of defining clear endpoints to assess the curative potential of gene therapies, especially in diseases like Parkinson's disease where symptomatic relief is often the primary goal.

Despite the promising preclinical and early clinical data, the status of gene therapy for Parkinson's disease remains cautious. Oertel and Schulz [11] review recent clinical trials that have not demonstrated efficacy in some cases, such as those targeting neurotrophic factors, highlighting the need for continued refinement in vector design, target selection, and delivery methods. The challenges include immune responses, limited transduction efficiency, and the complex, multifactorial nature of Parkinson's disease pathology.

In summary, gene therapy platforms for Parkinson's disease are


advancing with innovative vector technologies, targeted gene delivery, and regenerative approaches (Figure 1) [17]. While preclinical studies and early clinical trials show potential, the clinical outcomes to date have been mixed, emphasizing the need for improved biomarkers, optimized vectors, and comprehensive trial designs. The integration of molecular insights, such as gene expression profiling and biomarker development, will be crucial in refining these therapies and achieving meaningful, long-lasting benefits for Parkinson's disease patients. As research progresses, the hope remains that gene therapy will evolve into a viable disease-modifying treatment, ultimately transforming the management of Parkinson's disease.

## Molecular Targets and Therapeutic Strategies: Beyond Dopamine Replacement

While dopamine replacement with levodopa remains the cornerstone of Parkinson's disease management, its long-term use is associated with significant complications, including motor fluctuations and dyskinesias [18, 19]. Gene therapy strategies have thus evolved to move beyond mere symptomatic relief, aiming instead to restore durable dopaminergic function, provide neuroprotection, and directly modulate the dysfunctional neural circuits that underlie Parkinson's disease pathology (Table 1). These approaches leverage advanced molecular tools to address the root causes of neuronal dysfunction and death, offering the potential for disease modification. The following strategies represent the forefront of this investigative effort, each targeting a specific node within the complex pathophysiology of Parkinson's disease.

### Strategy 1: Enhanced dopamine synthesis

A primary strategy to enhance dopamine synthesis focuses on the enzyme aromatic L-amino acid decarboxylase (AADC), which is responsible for converting levodopa into dopamine [20, 21]. In Parkinson's disease, the progressive loss of dopaminergic neurons is accompanied by a significant decline in AADC activity, leading to inefficient conversion of oral levodopa and contributing to the 'on-off' motor fluctuations experienced by patients. Gene therapy approaches, such as Voyager therapeutics (VY)-AADC, seek to address this by



**Figure 1:** Summary of gene therapy approaches targeting Parkinson's disease pathophysiology [17].



**Table 1:** Key gene therapy strategies for Parkinson's disease beyond dopamine replacement.

| Strategy                    | Molecular target                                           | Therapeutic goal                         | Mechanism of action                                                                                                                                                                                   | Key challenge(s)                                                                                                                 |
|-----------------------------|------------------------------------------------------------|------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|
| Enhanced dopamine synthesis | AADC                                                       | Stabilize motor response to levodopa     | AAV-mediated delivery of the AADC gene to the striatum to improve conversion of oral levodopa to dopamine, creating a more reliable 'enzymatic pump'                                                  | Efficacy is contingent on continued levodopa administration; does not address underlying neurodegeneration                       |
| Neurotrophic support        | Glial cell line-derived neurotrophic factor (GDNF) or NRTN | Protect and restore dopaminergic neurons | AAV-mediated delivery of GDNF or NRTN genes to the striatum; the secreted protein is taken up by dopaminergic terminals and retrogradely transported to cell bodies to promote survival and sprouting | Achieving sufficient and uniform coverage of the target structure to demonstrate consistent clinical efficacy in trials          |
| Circuit modulation          | Glutamic acid decarboxylase (GAD)                          | Rebalance motor circuit activity         | AAV-mediated delivery of the GAD gene to the subthalamic nucleus, shifting its neurotransmitter output from excitatory (glutamate) to inhibitory (GABA), thereby dampening pathological overactivity  | A standalone symptomatic treatment that is independent of the dopaminergic system but does not directly slow disease progression |

using AAV vectors to deliver the AADC gene directly to the striatal neurons that remain [22, 23]. This intervention aims to re-sensitize the striatum to levodopa by increasing its local conversion to dopamine, thereby providing more stable and efficient dopamine signaling from each dose of medication.

The clinical application of AADC gene therapy involves the precise neurosurgical delivery of the AAV vector into the putamen, a key brain region involved in motor control that receives dense dopaminergic input. By elevating AADC levels in this structure, the therapy creates a localized 'enzymatic pump' capable of converting exogenous levodopa into dopamine more effectively [24]. Clinical trials have demonstrated that this approach is feasible and generally safe, with positron emission tomography imaging confirming increased AADC expression in the targeted putamen. Patients have shown encouraging results, including extended 'on' time without troublesome dyskinesias, reduced daily levodopa requirements, and overall improvements in motor function, suggesting a more efficient and sustained response to their standard medication [25, 26]. The promise of AADC enhancement lies in its ability to optimize the existing gold-standard therapy rather than replace it. This strategy effectively amplifies the efficacy of levodopa, making its administration more predictable and reducing the burden of motor complications. However, its success is inherently tied to the continued administration of levodopa and does not directly address the underlying neurodegeneration. Despite this limitation, AADC gene therapy represents a crucial step towards stabilizing dopaminergic replacement, offering a significant improvement in quality of life for patients with advanced Parkinson's disease who no longer respond reliably to conventional pharmacotherapy [27, 28].

## Strategy 2: Neurotrophic support

Moving beyond symptomatic management, a key therapeutic strategy involves providing neurotrophic support to rescue dying dopaminergic neurons and promoting the regeneration of their axonal projections. GDNF and its relative NRTN are potent survival factors for midbrain dopaminergic neurons [29, 30]. The rationale for their use in gene therapy is based on the observation that these neurons are particularly responsive to GDNF and NRTN signaling, which can activate pathways that enhance cell resilience, stimulate dopamine synthesis, and encourage neurite outgrowth. By delivering the genes encoding these factors directly to the striatum, the therapy aims to create a sustained, local source of trophic support, mimicking the natural environment that helps sustain these vulnerable cells [31].

In practice, AAV vectors are used to deliver the GDNF or NRTN gene (as in the CERE-120 trial for NRTN) to the striatum, where the proteins are produced and secreted [32, 33]. The goal is for these factors to be taken up by the terminals of the nigrostriatal neurons and retrogradely transported back to the cell bodies in the substantia

nigra, thereby reaching the neurons most at risk in Parkinson's disease. Preclinical studies in Parkinsonian non-human primates and other models have been highly promising, showing not only protection against toxin-induced degeneration but also evidence of functional recovery and regeneration of dopaminergic fibers, providing a strong rationale for human trials [34, 35].

Despite the compelling preclinical data, clinical trials of GDNF and NRTN gene therapy have yielded mixed outcomes. While the procedures have been well-tolerated, the primary efficacy endpoints in several phase II studies have not been consistently met, failing to demonstrate a statistically significant superiority over sham surgery in unified Parkinson's disease rating scale (UPDRS) scores. The challenges are thought to include insufficient coverage of the target region by the trophic factor, suboptimal dosing, and the possibility that the therapy may be most effective in earlier disease stages when a sufficient number of neurons remains to be rescued. Ongoing research is focusing on improving vector delivery systems, optimizing dosing regimens, and identifying patient subgroups most likely to benefit from this neuroprotective and potentially restorative approach.

## Strategy 3: Circuit modulation

An alternative to targeting dopamine directly is to modulate the dysfunctional neural circuits that cause Parkinson's disease symptoms. Parkinson's disease is characterized by overactivity of the subthalamic nucleus, a key node within the basal ganglia-thalamocortical motor circuit [36, 37]. This overactivity, driven by a loss of dopaminergic inhibition, contributes to the hallmark hypokinetic features of the disease. Gene therapy strategies for circuit modulation aim to rebalance this network by converting the excitatory output of the subthalamic nucleus into inhibitory signaling, effectively providing a 'chemical neuromodulation' that mimics the effect of deep brain stimulation [38].

This approach has been pioneered with AAV-mediated delivery of the gene for GAD, the enzyme that synthesizes the inhibitory neurotransmitter GABA. The therapy, known as AAV-GAD (e.g., NAB-7), involves injecting the vector unilaterally or bilaterally into the subthalamic nucleus [39]. The subsequent expression of GAD in subthalamic nucleus neurons enables them to produce and release GABA, shifting their neurotransmission from excitatory (glutamatergic) to inhibitory (GABAergic) [40]. This localized change dampens the pathological over-excitation of the subthalamic nucleus and its downstream targets, thereby helping to normalize the entire motor circuit and alleviate parkinsonian motor signs.

Clinical trials of AAV-GAD gene therapy have demonstrated its safety and provided evidence of efficacy. A landmark phase II randomized controlled trial showed statistically significant improvements in motor function on the side of the body contralateral



to the treatment compared to sham surgery, as measured by the UPDRS [41, 42]. The benefits were sustained over long-term follow-up, suggesting a durable effect. This strategy offers a distinct advantage: it is not dependent on the presence of dopaminergic neurons or the administration of levodopa, making it a truly direct and independent intervention for circuit dysfunction. By focusing on the network-level pathology, circuit modulation via GAD gene therapy represents a novel and promising symptomatic treatment that operates through a mechanism entirely different from dopamine replacement [43, 44].

In summary, gene therapy strategies are advancing beyond traditional dopamine replacement to provide more sophisticated interventions. These approaches aim to enhance the efficiency of levodopa metabolism, provide neurotrophic support for degenerating neurons, and directly rebalance pathological brain circuits. While each strategy operates through a distinct mechanism—enzymatic enhancement, trophic factor delivery, or neuromodulation—they share the common goal of achieving more durable and effective symptomatic control. The continued refinement of these platforms holds significant promise for improving long-term outcomes for patients with Parkinson's disease.

### Viral Vector Platforms: The Engine for Gene Delivery

The successful implementation of gene therapy for Parkinson's disease is fundamentally dependent on the viral vectors used to deliver therapeutic genetic material. These engineered viruses serve as molecular vehicles, designed to transport genes into specific target cells within the central nervous system while being stripped of their ability to replicate and cause disease. The ideal vector must achieve efficient transduction of neurons, sustain therapeutic levels of transgene expression, and elicit a minimal immune response to ensure both safety and long-term efficacy. Among the various platforms developed, adeno-associated viruses and LV have emerged as the leading workhorses for neurological applications, each offering a distinct set of advantages and challenges that shape their clinical use (Table 2).

#### Adeno-associated virus: The gold standard for neurological delivery

AAV has become the predominant vector for *in vivo* gene therapy in Parkinson's disease due to its favorable safety profile and strong tropism for neurons [45]. AAV is a small, non-enveloped, single-stranded DNA virus that is naturally replication-deficient and not known to cause human disease [46]. Its primary safety advantage lies in its non-integrating nature; the AAV genome typically persists in the nucleus as a stable episome, which significantly reduces the risk of insertional mutagenesis that has been a concern with other viral vectors. This characteristic makes AAV particularly suitable for disorders where long-term, but not necessarily permanent, transgene expression in non-dividing cells like neurons is desired [47].

A key feature of AAV is its capacity to drive high levels of

transgene expression, though this is often characterized as 'transient' in comparison to integrating vectors. In the context of non-dividing neuronal cells, AAV-mediated expressions can persist for many years, as evidenced by long-term follow-up studies in both animal models and clinical trials [48]. However, the episomal DNA can be gradually diluted in dividing cells, and the initial high-level expression may wane over a period of years, which could be a consideration for lifelong diseases. Furthermore, a significant challenge with AAV is its immunogenicity; pre-existing neutralizing antibodies in a substantial portion of the population can block transduction, and the capsid itself can trigger a cell-mediated immune response that may eliminate transduced cells, potentially limiting re-dosing options [49, 50].

The versatility of the AAV platform is greatly enhanced by its numerous natural serotypes and engineered capsid variants, which confer different tropisms for various tissues. For Parkinson's disease, AAV serotype 2 has been the most extensively studied in clinical trials, demonstrating a strong affinity for neurons within the striatum and substantia nigra [51]. The choice of promoter is equally critical for targeting specific brain regions; ubiquitous promoters like chicken  $\beta$ -Actin can drive strong general expression, while neuron-specific promoters (e.g., synapsin) or synthetic promoters can be used to restrict transgene expression to dopaminergic or GABAergic neurons, enhancing specificity and safety [52]. This ability to fine-tune delivery through serotype and promoter selection is a cornerstone of modern AAV-based gene therapy design.

#### LV: A platform for stable, long-term expression

LV, a subclass of retroviruses, presents a contrasting profile to AAV and offers distinct advantages for certain gene therapy strategies. LVs are enveloped, single-stranded RNA viruses that are capable of infecting both dividing and non-dividing cells, including post-mitotic neurons [53]. The defining characteristic of LV is its ability to integrate its genetic payload into the host cell's genome. This integration facilitates stable, long-term transgene expression, as the therapeutic gene is replicated and passed on to all daughter cells during cell division, making it an ideal candidate for strategies that require permanent genetic modification, such as those involving stem or progenitor cells [54].

The integrating nature of LV provides a solution to the potential decline of transgene expression observed with non-integrating vectors over very long periods. For a progressive neurodegenerative disease like Parkinson's, this promises a 'one-and-done' therapeutic effect that is sustained for the lifetime of the patient [55]. This stability is a significant advantage, but it is counterbalanced by a more complex safety consideration: the risk of insertional mutagenesis. While modern, self-inactivating LV designs have greatly reduced this risk by removing viral enhancer/promoter elements, the theoretical possibility of disrupting a tumor suppressor gene or activating an oncogene through random integration remains a carefully monitored aspect of its clinical development [56].

**Table 2:** Comparison of primary viral vector platforms for Parkinson's disease gene therapy.

| Feature                      | Adeno-associated virus                                                 | Lentivirus                                                                     |
|------------------------------|------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Virus type                   | Small, non-enveloped, single-stranded DNA virus                        | Enveloped, single-stranded RNA virus (retrovirus)                              |
| Genomic integration          | Non-integrating (persists as episome)                                  | Integrating (stable insertion into host genome)                                |
| Expression duration          | Long-term but potentially declining over years (transient)             | Stable, permanent expression due to integration                                |
| Primary safety concern       | Immunogenicity (humoral and cell-mediated)                             | Insertional mutagenesis (theoretical risk)                                     |
| Typical clinical application | Direct <i>in vivo</i> delivery to neurons                              | Often used for <i>ex vivo</i> modification of cells (e.g., stem cells)         |
| Key advantage                | Favorable safety profile, strong neuronal tropism, clinical experience | Guaranteed long-term expression in dividing cells, lower pre-existing immunity |





From a practical standpoint, LV vectors face challenges related to manufacturing and immunogenicity. The production of high-titer, clinical-grade LV is more complex and costlier than for AAV, due to its larger size and enveloped structure [57]. While LV generally elicits a lower humoral immune response against its capsid compared to AAV, the potential for immune reactions to transgene products or residual cellular antigens from the production process still exists. Consequently, LV is often considered for *ex vivo* applications, such as engineering patient-derived cells outside the body before transplantation, though its use in direct *in vivo* central nervous system gene delivery is also being actively explored for Parkinson's disease [58].

### Comparative profiles

When comparing AAV and LV for Parkinson's disease gene therapy, their contrasting genomic strategies define their clinical applications. AAV, as a non-integrating vector, is ideally suited for strategies requiring high-level, sustained protein expression in stable neuronal populations, such as the continuous secretion of enzymes like AADC or neurotrophic factors like GDNF [59]. Its relatively simple production and strong track record in clinical trials have cemented its role as the current vector of choice for direct *in vivo* delivery. In contrast, LV's integrating capacity makes it a powerful tool for strategies where permanent genetic modification is essential, such as in regenerative approaches using modified stem cells that require the transgene to be maintained through multiple cell divisions [60].

The immune response presents another critical point of comparison. AAV's widespread prevalence in the human population often leads to pre-existing neutralizing antibodies, which can exclude a significant number of patients from treatment or necessitate robust screening [61]. The capsid-specific T-cell response can also complicate therapy. LV, derived from human immunodeficiency virus-1 but extensively engineered for safety, generally has lower pre-existing immunity in humans, which is a distinct advantage [62]. However, the immune response to the transgene product itself is a variable independent of the vector choice and must be evaluated on a case-by-case basis for any therapeutic strategy.

Ultimately, the choice between AAV and LV is not a matter of superiority but of strategic alignment with the therapeutic goal. For most current strategies aiming to modulate the function of existing neurons in the Parkinsonian brain—be it for enzyme replacement, neurotrophic support, or circuit modulation—AAV offers a proven, efficient, and relatively safe platform [63]. For next-generation therapies that involve cell replacement or require guaranteed, lifelong expression of a therapeutic gene from a specific progenitor population, LV's stable integration profile may offer a more durable solution. The ongoing refinement of both vector systems, including the development of novel AAV capsids with enhanced tropism and reduced immunogenicity, as well as safer LV integration systems, will continue to expand the toolkit available for combating Parkinson's disease.

### Surgical Delivery: The Critical Role of Convection-enhanced Delivery

The success of gene therapy for Parkinson's disease hinges not only on the design of the viral vector but also on the method of its delivery into the brain. The blood-brain barrier effectively prevents the passage of large molecules and viral particles from the bloodstream, necessitating direct intracerebral administration [64]. However, the human brain is a vast and complex structure, and the pathological changes in Parkinson's disease affect large, specific regions such as the

striatum [65]. Simply injecting a therapeutic agent into these areas is insufficient, as it results in a limited, unpredictable spread dependent on diffusion, which is too slow and restricted to cover the necessary volume of tissue for a meaningful clinical effect.

To overcome the severe limitations of simple bolus injections, the field has adopted convection-enhanced delivery as the gold standard for administering gene therapies. Convection-enhanced delivery is a sophisticated neurosurgical technique that uses a positive pressure gradient to push the infusate (the viral vector solution) directly through the extracellular space of the brain [66]. Unlike diffusion, which is passive and slow, convection-enhanced delivery is an active, continuous infusion process that enables the widespread and homogeneous distribution of therapeutic agents throughout large target structures, making it possible to treat the extensive neuronal networks involved in Parkinson's disease [67].

The convection-enhanced delivery procedure is performed with extreme precision using stereotactic neurosurgical guidance. Following detailed magnetic resonance imaging planning, one or multiple catheters are navigated to pre-defined coordinates within the target structure, most commonly the post-commissural putamen, which is the main input structure of the degenerating nigrostriatal pathway [68]. A pump system then slowly and steadily infuses the viral vector solution over several hours. This controlled, continuous flow 'conveys' the therapy through the brain tissue, creating a large, predictable volume of distribution that can be tailored to match the anatomical boundaries of the target region.

### The critical importance of widespread distribution

The need for comprehensive coverage is paramount because Parkinson's disease pathology affects the entire striatum. A therapy designed to enhance dopamine synthesis, like AADC gene therapy, must be delivered to the vast majority of putaminal neurons to meaningfully increase the brain's capacity to convert levodopa [69]. Similarly, a neurotrophic factor like GDNF must saturate the striatum to be taken up by the remaining terminals of dopaminergic neurons and retrogradely transported to their cell bodies in the substantia nigra [70]. Incomplete coverage creates 'therapeutic deserts'—untreated areas where the degenerative process continues unabated, severely limiting the potential for significant clinical improvement.

The stark consequences of inadequate delivery were highlighted in early gene therapy trials, where post-operative imaging revealed highly variable and often insufficient vector distribution [71]. In some cases, only a small fraction of the intended target structure was transduced. This variability is now understood to be a major contributor to the inconsistent clinical outcomes observed across different trials and individual patients. It became clear that a patient who received robust coverage of the putamen was far more likely to show motor improvement than a patient with patchy, limited distribution, even when both received the same therapeutic vector dose.

Therefore, the efficacy of gene therapy is inextricably linked to the accuracy and completeness of its surgical delivery. The therapeutic agent, no matter how potent, can only act on the neurons it reaches. Ensuring that the vector is distributed throughout the relevant neuroanatomical structures is now considered as important as the molecular design of the therapy itself [72]. This understanding has shifted the paradigm in trial design, placing a heavy emphasis on real-time monitoring and verification of delivery, making convection-enhanced delivery technique a critical variable in determining success or failure.



## Technical execution and monitoring of convection-enhanced delivery

The practical execution of convection-enhanced delivery is technically demanding and requires meticulous planning and execution. The trajectory of the catheter must be carefully planned to avoid piercing blood vessels or traversing sulci and ventricles, as these can act as low-resistance pathways that cause the infusate to leak away from the target tissue, a phenomenon known as 'backflow' [73]. To mitigate this, stepped catheters are often used, where a larger outer cannula is placed just short of the target, and a thinner inner catheter is advanced through it to the final target point, creating a tight seal and facilitating direct delivery into the parenchyma.

To address the critical challenge of ensuring accurate coverage, the field has developed advanced real-time imaging techniques. Co-infusing the viral vector with a contrast agent, such as gadoteridol, allows for the infusion to be visualized using real-time intraoperative magnetic resonance imaging [74]. This provides the surgical team with immediate feedback on the distribution pattern, enabling them to adjust the flow rate or even pause and reposition the catheter if backflow or leakage into non-target areas is observed. This iterative, image-guided approach transforms the procedure from a blind injection into a controlled, monitored delivery, maximizing the likelihood of complete target coverage.


The impact of refined convection-enhanced delivery on clinical outcomes is profound. Later-phase trials that have incorporated these advanced delivery protocols, including real-time intraoperative magnetic resonance imaging guidance, have demonstrated more

consistent and robust coverage of the putamen [75, 76]. This technical improvement correlates strongly with better and more reproducible clinical results, such as significant increases in AADC enzyme activity observed on positron emission tomography scans and corresponding improvements in motor scores [77]. The evolution of convection-enhanced delivery from a conceptual technique to a clinically validated, image-guided platform represents a monumental step forward, proving that in brain gene therapy, delivery is not just a step in the process—it is a fundamental determinant of therapeutic efficacy.

In summary, convection-enhanced delivery has emerged as the indispensable surgical platform for achieving the widespread and homogeneous distribution of gene therapies required for treating Parkinson's disease. This sophisticated technique overcomes the limitations of simple injections by actively perfusing large target structures, such as the putamen. The accuracy and completeness of this delivery are now understood to be as critical as the therapeutic vector itself, directly influencing clinical outcomes. Consequently, the integration of real-time magnetic resonance imaging monitoring has become a vital component for ensuring accurate targeting and optimizing the potential for therapeutic success.

## Clinical Trials

A phase 1 trial by Christine et al. [76] (NCT01973543) of putaminal AADC gene therapy (VY-AADC01) for Parkinson's disease, guided by magnetic resonance imaging, demonstrated several key findings regarding safety, putaminal coverage, enzyme activity, and clinical outcomes (Figure 2). The surgical procedure for administering VY-




**Figure 2:** This figure displays the motor function (UPDRS-III) response to low (threshold) and high (suprathreshold) doses of intravenous levodopa, both before and 6 months after treatment with VY-AADC01. Each row represents a different patient cohort (1, 2, and 3). The key finding is that after treatment, cohort 2's response to a low dose of levodopa (Panel C) was as effective as their response to a high dose was before treatment (Panel D), indicating a significant improvement in drug sensitivity. Lower scores represent better motor function [76].



AADC01 was generally well tolerated by the participants. Most subjects (14 out of 15) were able to return home within two days of surgery. Only one participant experienced a serious adverse event, which involved deep venous thrombosis, pulmonary embolus, and subsequent atrial fibrillation. This event was likely linked to immobility during surgery and resolved with anticoagulation and antiarrhythmic treatment. deep venous thrombosis prophylaxis was later added to the surgical protocol, and no further such events occurred. No vector-related serious adverse events were reported. The most common vector-related adverse event observed was transient dyskinesia, which typically emerged around one-month post-surgery when AADC expression stabilized. These dyskinesias responded to reductions in antiparkinsonian medications. The novel intraoperative magnetic resonance imaging guidance technique facilitated targeted delivery of VY-AADC01, allowing for optimization of administration and increased putaminal coverage compared to previous trials. This method allowed for real-time monitoring of the infusate's anatomic spread. Ascending doses of VY-AADC01 resulted in increased putaminal coverage: 21% for cohort 1, 34% for cohort 2, and 42% for cohort 3. Post-operative magnetic resonance imaging evaluations showed volumetric coverage of 20.7% for cohort 1, 33.5% for cohort 2, and 42.3% for cohort 3. The increased putaminal coverage correlated strongly with dose-dependent increases in enzyme activity, as measured by 18F-dopa positron emission tomography scans. At 6 months, 18F-dopa uptake increased by 13% in cohort 1, 56% in cohort 2, and 79% in cohort 3. Corresponding to the increases in enzyme activity, there were dose-dependent reductions in antiparkinsonian medication. At 6 months, medication was reduced by -15% for cohort 1, -33% for cohort 2, and -42% for cohort 3. These reductions were maintained in cohorts 2 and 3 through the last follow-up. During the 12 months, all cohorts showed increases in patient-reported ON-time without troublesome dyskinesia (1.6, 3.3, and 1.5 h for cohorts 1, 2, and 3, respectively). These improvements were stable or further improved with continued follow-up. Patient-reported

quality of life was stable or improved across cohorts. For cohorts 2 and 3, Parkinson's disease questionnaire (PDQ-39) scores showed clinically meaningful improvements in 12 months. Dose-related improvements were observed in UPDRS-III scores, particularly in the off-medication state, with reductions across all cohorts sustained through 36 months for cohort 1. The intravenous levodopa substudy showed that after AADC gene therapy, both threshold and suprathreshold infusions led to more rapid and complete improvement in UPDRS-III score. In summary, the study concluded that magnetic resonance imaging guided delivery of VY-AADC01 was well-tolerated and led to dose-dependent increases in enzyme expression and significant clinical improvements, including enhanced putaminal coverage, reduced medication needs, and improved ON-time and quality of life for Parkinson's patients.

A study by Nutt et al. [24] investigated the effects of AADC gene therapy (VY-AADC01) on levodopa response in patients with Parkinson's disease (Figure 3). The findings highlight significant improvements in motor function and levodopa efficacy, albeit with an increase in dyskinesia. Out of the 15 patients enrolled in the Parkinson's disease-1101 study, 13 participated in this specific substudy. This included all 5 patients from cohort 1, all 5 from cohort 2, and 3 out of 5 from cohort 3. Two patients from cohort 3 were unable to participate due to travel limitations. While baseline characteristics were generally balanced across cohorts, cohort 1 had lower UPDRS III scores, and cohort 3 had higher unified Dyskinesia rating scale scores. VY-AADC01 significantly improved motor responses to intravenous levodopa under control conditions. The most prominent effects of VY-AADC01 were observed with threshold (lower dose) levodopa infusions. There was a 168% increase in the mean area under the curve (AUC) for UPDRS-III motor score responses to threshold levodopa infusions post-VY-AADC01. For suprathreshold infusions, the AUC increased by 67%. The magnitude and duration of responses to threshold levodopa increased across all cohorts after gene therapy,



**Figure 3:** Graph shows how finger-tapping speed changed over time during and after low-dose and high-dose levodopa infusions, comparing performance before and after VY-AADC01 treatment. An increase in speed indicates improvement [24].





with more rapid onset and prolonged duration of  $\geq 30\%$  reduction in UPDRS-III scores. An independent measure of bradykinesia, finger-tapping speeds, also showed improvement after AADC gene delivery. Large increases in AUC were noted for both threshold (162%) and suprathreshold (113%) levodopa doses post-VY-AADC01. As expected, dyskinesia scores were higher after gene therapy with levodopa infusion. The mean overall AUC for dyskinesia increased by 208% for threshold levodopa conditions and 72% for suprathreshold conditions post-VY-AADC01. The duration of dyskinesia was longer across all cohorts in the suprathreshold condition after VY-AADC01 administration. After VY-AADC01 administration, there were trends toward improvement in off-medication UPDRS-III scores and finger-tapping speeds at baseline (i.e., when patients had been without levodopa and other anti-parkinsonian medications overnight). This suggests increased dopamine synthesis from endogenous levodopa. Mild or moderate adverse events were reported in 5 participants during pre-VY-AADC01 levodopa challenges and in 2 participants post-VY-AADC01 infusions. No arrhythmias were detected. In summary, the gene therapy significantly enhanced the motor response to levodopa, particularly at lower doses, and improved baseline motor function in Parkinson's disease patients. However, this benefit was accompanied by an increase in dyskinesia, which is a known side effect of dopaminergic therapies in advanced Parkinson's disease. These results support the continued clinical development of AADC gene therapy for Parkinson's disease.

## Clinical Trial Designs and Endpoint Challenges

The clinical evaluation of gene therapies for Parkinson's disease presents a unique set of methodological and ethical challenges, largely stemming from their invasive nature as surgical interventions. Unlike pharmaceutical trials, where placebo pills are standard, blinding participants in a surgical trial is complex and ethically nuanced [78]. To account for the powerful placebo effects associated with brain surgery, some trials have employed a sham surgery control arm, where participants undergo a full craniotomy and burr hole drilling but do not receive the actual viral vector infusion [79]. While this design provides the highest level of evidence by controlling both the physiological impact of the surgery and participant expectation, it raises significant ethical concerns regarding the risks imposed on control subjects who do not receive a potential therapeutic benefit.

The choice of primary endpoints is critical for demonstrating efficacy and must align with the therapeutic strategy's proposed mechanism of action. The most widely used endpoint is the UPDRS, specifically part III (motor examination), assessed in the practically defined 'off-medication state' [80]. Measuring patients after withholding dopaminergic medication for typically 12 h aims to isolate the therapy's effect on baseline motor function, independent of concurrent levodopa [81]. A statistically significant improvement in the 'off-medication UPDRS is considered a robust indicator of a direct biological effect, suggesting the therapy is providing a new, sustained source of functional improvement [82]. For therapies aimed at improving the response to levodopa, such as AADC-enhancement, a key endpoint is the reduction in daily 'off' time, as recorded by patient diaries. 'Off' time refers to the debilitating periods when medication wears off, and motor symptoms return.

Successful therapy should lead to a more stable and prolonged response to each dose of levodopa, thereby increasing 'on' time without troublesome dyskinesias and reducing the total daily 'off' time [83]. This endpoint directly translates to a tangible improvement in a patient's

daily life, making it a highly clinically relevant outcome measure alongside the more objective motor score. Patient-reported outcomes and quality of life measures, such as the PDQ-39, provide an essential complement to clinician-rated motor scales [84]. These instruments capture the therapy's impact on non-motor symptoms, emotional well-being, and activities of daily living from the patient's perspective. A therapy that shows a statistically significant improvement in motor scores but fails to demonstrate a meaningful benefit in a patient's self-reported quality of life may be of limited real-world value [85]. Therefore, a comprehensive assessment requires a multi-faceted endpoint approach that includes objective motor scores, diary data, and validated quality of life measures.

One of the most significant challenges in Parkinson's disease therapeutics is definitively proving a 'disease-modifying' effect—that is, demonstrating that a treatment slows or halts the underlying progression of neurodegeneration [86, 87]. In gene therapy trials, this is exceptionally difficult. A sustained symptomatic benefit, even over years, does not necessarily equate to disease modification, as it could simply represent a long-lasting pharmacological effect. Differentiating between these possibilities requires sophisticated trial designs, such as delayed-start or washout protocols, and the use of biomarkers that can directly measure the integrity of the nigrostriatal system, like dopamine transporter single-photon emission computed tomography imaging [88, 89]. The variable and progressive nature of Parkinson's disease itself adds another layer of complexity to trial design and interpretation [90]. The rate of clinical decline can differ significantly between individuals, and the magnitude of the placebo effect can be substantial and unpredictable. This high background noise requires large patient cohorts and long observation periods to detect a true signal of efficacy.

Furthermore, the stage of disease at which a therapy is administered is crucial; a neuroprotective agent may only be effective in early-stage patients who still possess a sufficient number of neurons to rescue, a window that may have closed for patients in advanced stages enrolled in many current trials [91]. Long-term follow-up is paramount for evaluating the durability of gene therapy effects and monitoring for delayed adverse events. Given that these therapies are designed to be a one-time intervention, it is essential to track whether the transgene expression and clinical benefit are maintained for many years. A decline in efficacy after several years would suggest that the chosen vector platform or delivery method may not be sufficient for lifelong treatment [92, 93]. Consequently, regulatory agencies now mandate extended follow-up periods, often spanning five to fifteen years, to fully understand the risk-benefit profile of these novel biological interventions.

In summary, designing clinical trials for Parkinson's disease gene therapy requires a careful balance between scientific rigor, ethical considerations, and clinical relevance. The use of sham surgery controls, while contentious, remains a powerful tool for isolating true efficacy from the placebo effect. The field continues to rely on a combination of 'off-medication motor scores, patient diaries, and quality-of-life measures as primary endpoints, though there is a clear and pressing need for validated biomarkers of disease progression. As the field advances, future trial designs must not only demonstrate symptomatic improvement but also develop methodological tools to convincingly prove that these interventions can fundamentally alter the course of the disease.

## Safety and Immunogenicity Profile

The safety profile of gene therapy for Parkinson's disease is a





critical consideration and is broadly divided into risks associated with the surgical procedure itself and those inherent to the viral vector and its genetic payload. The primary surgical risks are consistent with any stereotactic neurosurgical intervention and include intracranial hemorrhage, infection, and perioperative complications [94]. While these events are rare in experienced centers, they represent a significant potential morbidity, underscoring the necessity for highly skilled surgical teams and rigorous patient selection to minimize these inherent procedural hazards.

Beyond surgery, vector-related safety is paramount. For AAV vectors, the predominant platform, the primary biological concern is the host immune response [95]. This can manifest as a humoral response, where pre-existing or newly formed neutralizing antibodies bind to the viral capsid and prevent cellular entry, thereby reducing transduction efficiency. More significantly, a cell-mediated T-cell response can be directed against the AAV capsid proteins presented on the transduced cells, potentially leading to the elimination of those cells and a consequent loss of transgene expression, which has been observed in other systemic gene therapy fields [96, 97]. The immune system can also mount a response against the newly expressed transgene product itself, treating it as a foreign antigen. This is a particular concern for therapies delivering non-human proteins or even modified human proteins at supraphysiological levels. An adaptive immune response against the therapeutic protein could not only nullify the treatment's benefit but also potentially lead to inflammation and damage to the very neurons the therapy aims to protect [98, 99]. The extent of this risk depends on factors such as the patient's prior immune tolerance to the protein and the specificity of the promoter driving its expression.

A direct consequence of these immune responses, particularly the humoral response to the AAV capsid, is the challenge of re-administration. The initial exposure often induces a robust and long-lasting increase in neutralizing antibodies, effectively precluding a second treatment with the same AAV serotype in the future [39]. This 'one-shot' nature of AAV therapy places immense pressure on achieving a sufficient therapeutic effect from a single procedure and optimal delivery, as the opportunity for dose adjustment or re-treatment is severely limited [100]. Long-term follow-up data from ongoing clinical trials, some extending beyond five to ten years, have provided reassuring insights into the chronic safety of these intracerebral interventions. To date, there has been no evidence of systemic malignancy or neoplastic transformation in the brain directly linked to AAV vectors. This supports preclinical safety data indicating that AAV's non-integrating nature presents a very low risk of insertional mutagenesis, a historical concern with earlier-generation retroviral vectors [101, 102].

Similarly, for lentiviral vectors, which are integrating by design, long-term safety data from *ex vivo* therapies in other diseases and emerging *in vivo* data have been encouraging [103]. The use of self-inactivating designs, which remove the viral enhancer and promoter sequences, has substantially mitigated the risk of oncogene activation that was associated with earlier gamma-retroviral vectors. Continued monitoring of patients in Parkinson's disease trials will be essential to fully confirm the long-term safety profile of these platforms within the central nervous system [2]. Overall, the collective experience from clinical trials indicates that gene therapy for Parkinson's disease, when delivered with precision, is generally well-tolerated from a neurological standpoint. The most commonly reported adverse events are often related to the surgical procedure or the underlying progression of Parkinson's disease rather than the vector itself. The absence of serious, widespread vector-related toxicity or tumorigenicity in long-term

studies is a significant positive finding that supports the continued investigation of this therapeutic modality [104, 105].

In summary, while the surgical risks and potential for immunogenicity present clear challenges, the safety profile of AAV and LV-based gene therapies for Parkinson's disease has been manageable within the context of clinical trials. The primary safety concerns remain the one-time procedural risks and the potential for immune-mediated attenuation of efficacy. Ongoing research is focused on developing strategies to modulate immune responses, engineer stealthier capsids, and employ immunosuppressive regimens around the time of surgery to maximize both the initial success and the durability of these promising treatments.

## Conclusion

The future trajectory of gene therapy for Parkinson's disease will be defined by a shift from broad symptomatic strategies to precisely targeted interventions informed by the growing understanding of the disease's genetic and molecular subtypes. Next-generation approaches will likely involve combinatorial strategies, such as co-delivering a neurotrophic factor to protect vulnerable neurons alongside an enzyme for enhanced dopamine synthesis, offering a multi-pronged attack on the disease's pathology. Furthermore, the advent of novel engineered capsids with enhanced tropism for specific neuronal populations and reduced immunogenicity, coupled with regulatable promoter systems that allow for external control of transgene expression, promises to significantly improve the safety, efficacy, and controllability of these treatments.

Ultimately, the goal remains the development of a definitive disease-modifying therapy. Achieving this will require a concerted effort to identify and validate biomarkers that can stratify patients, monitor target engagement, and objectively measure disease progression. As vector technology, delivery techniques, and clinical trial designs continue to mature in parallel, gene therapy is poised to transition from an experimental modality to a cornerstone of personalized neurology. The integration of these advanced platforms holds the transformative potential to not just alleviate symptoms but to fundamentally alter the progressive course of Parkinson's disease, offering renewed hope for long-term therapeutic success.

## Acknowledgements

None.

## Conflict of Interest

None.

## References

- Sharma A, Mishra SS, Singh S (2024) Gene Therapy, OMICS Approaches, and Translational Neurodegenerative Models: Recent Advancements and Future Perspectives. In *Neurodegenerative Diseases*. CRC Press, pp 206-223.
- Stocchi F, Bravi D, Emmi A, Antonini A (2024) Parkinson disease therapy: current strategies and future research priorities. *Nat Rev Neurol* 20: 695-707. <https://doi.org/10.1038/s41582-024-01034-x>
- Firdaus Z, Li X (2024) Unraveling the genetic landscape of neurological disorders: insights into pathogenesis, techniques for variant identification, and therapeutic approaches. *Int J Mol Sci* 25: 2320. <https://doi.org/10.3390/ijms25042320>
- Tanaka M (2025) Parkinson's disease: bridging gaps, building biomarkers, and reimagining clinical translation. *Cells* 14: 1161. <https://doi.org/10.3390/cells14151161>
- Ntetsika T, Papathoma PE, Markaki I (2021) Novel targeted therapies for Parkinson's disease. *Mol Med* 27: 1-20. <https://doi.org/10.1186/s10020-021-00279-2>



6. Nimgampalle M, Chakravarthy H, Sharma S, Shree S, Bhat AR, et al. (2023) Neurotransmitter systems in the etiology of major neurological disorders: emerging insights and therapeutic implications. *Ageing Res Rev* 89: 101994. <https://doi.org/10.1016/j.arr.2023.101994>
7. Chopade P, Chopade N, Zhao Z, Mitragotri S, Liao R, et al. (2023) Alzheimer's and Parkinson's disease therapies in the clinic. *Bioeng Transl Med* 8: 1-23. <https://doi.org/10.1002/btm2.10367>
8. Perovnik M, Rus T, Schindlbeck KA, Eidelberg D (2023) Functional brain networks in the evaluation of patients with neurodegenerative disorders. *Nat Rev Neurol* 19: 73-90. <https://doi.org/10.1038/s41582-022-00753-3>
9. Feng LR, Maguire-Zeiss KA (2010) Gene therapy in Parkinson's disease: rationale and current status. *CNS Drugs* 24: 177-192. <https://doi.org/10.2165/11533740-000000000-00000>
10. O'Connor DM, Boulis NM (2015) Gene therapy for neurodegenerative diseases. *Trends Mol Med* 21: 504-512. <https://doi.org/10.1016/j.molmed.2015.06.001>
11. Oertel W, Schulz JB (2016) Current and experimental treatments of Parkinson disease: a guide for neuroscientists. *J Neurochem* 139: 325-337. <https://doi.org/10.1111/jnc.13750>
12. Abignano G, Buch M, Emery P, Del Galdo F (2011) Biomarkers in the management of scleroderma: an update. *Curr Rheumatol Rep* 13: 4-12. <https://doi.org/10.1007/s11926-010-0140-z>
13. Deverman BE, Ravina BM, Bankiewicz KS, Paul SM, Sah DW (2018) Gene therapy for neurological disorders: progress and prospects. *Nat Rev Drug Discov* 17: 641-659. <https://doi.org/10.1038/nrd.2018.110>
14. Rhee YH, Ko JY, Chang MY, Yi SH, Kim D, et al. (2011) Protein-based human iPS cells efficiently generate functional dopamine neurons and can treat a rat model of Parkinson disease. *J Clin Invest* 121: 2326-2335. <https://doi.org/10.1172/jci45794>
15. Kefalopoulou Z, Politis M, Piccini P, Mencia N, Bhatia K, et al. (2014) Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. *JAMA Neurol* 71: 83-87. <https://doi.org/10.1001/jamaneurol.2013.4749>
16. Corbacioglu S, Frangoul H, Locatelli F, Hobbs W, Walters M (2024) Defining curative endpoints for transfusion-dependent  $\beta$ -thalassemia in the era of gene therapy and gene editing. *Am J Hematol* 99: 422-429. <https://doi.org/10.1002/ajh.27166>
17. Szunyogh S, Carroll E, Wade-Martins R (2025) Recent developments in gene therapy for Parkinson's disease. *Mol Ther* 33: 2052-2064. <https://doi.org/10.1016/j.ymthe.2025.03.030>
18. di Biase L, Pecoraro PM, Carbone SP, Caminiti ML, Di Lazzaro V (2023) Levodopa-induced dyskinesias in Parkinson's disease: an overview on pathophysiology, clinical manifestations, therapy management strategies and future directions. *J Clin Med* 12: 4427. <https://doi.org/10.3390/jcm12134427>
19. Riederer P, Strobel S, Nagatsu T, Watanabe H, Chen X, et al. (2025) Levodopa treatment: impacts and mechanisms throughout Parkinson's disease progression. *J Neural Transm* 132: 743-779. <https://doi.org/10.1007/s00702-025-02893-4>
20. Tripathi RK, Goyal L, Singh S (2024) Potential therapeutic approach using aromatic l-amino acid decarboxylase and glial-derived neurotrophic factor therapy targeting putamen in Parkinson's disease. *Curr Gene Ther* 24: 278-291. <https://doi.org/10.2174/0115665232283842240102073002>
21. Sternberg Z (2024) Neurodegenerative etiology of aromatic l-amino acid decarboxylase deficiency: a novel concept for expanding treatment strategies. *Mol Neurobiol* 61: 2996-3018. <https://doi.org/10.1007/s12035-023-03684-2>
22. Ng J, Barral S, Waddington SN, Kurian MA (2023) Gene therapy for dopamine dyshomeostasis: from Parkinson's to primary neurotransmitter diseases. *Mov Disord* 38: 924-936. <https://doi.org/10.1002/mds.29416>
23. Khorkova O, Hsiao J, Wahlestedt C (2021) Nucleic acid-based therapeutics in orphan neurological disorders: recent developments. *Front Mol Biosci* 8: 1-24. <https://doi.org/10.3389/fmolb.2021.643681>
24. Nutt JG, Curtze C, Hiller A, Anderson S, Larson PS, et al. (2020) Aromatic L-amino acid decarboxylase gene therapy enhances levodopa response in Parkinson's disease. *Mov Disord* 35: 851-858. <https://doi.org/10.1002/mds.27993>
25. Tambasco N, Romoli M, Calabresi P (2018) Levodopa in Parkinson's disease: current status and future developments. *Curr Neuropharmacol* 16: 1239-1252. <https://doi.org/10.2174/1570159x15666170510143821>
26. Chen F, Zhou C (2025) Levodopa-induced dyskinesia in Parkinson's disease: an updated review of pharmacological treatments. *Front Aging Neurosci* 17: 1-15. <https://doi.org/10.3389/fnagi.2025.1684885>
27. Van Laar AD, Van Laar VS, San Sebastian W, Merola A, Elder JB, et al. (2021) An update on gene therapy approaches for Parkinson's disease: restoration of dopaminergic function. *J Parkinsons Dis* 11: S173-S182. <https://doi.org/10.3233/jpd-212724>
28. Christine CW, Richardson RM, Van Laar AD, Thompson ME, Fine EM, et al. (2022) Safety of AADC gene therapy for moderately advanced Parkinson disease: three-year outcomes from the PD-1101 trial. *Neurology* 98: e40-e50. <https://doi.org/10.1212/wnl.0000000000012952>
29. Tenenbaum L, Humbert-Claude M (2017) Glial cell line-derived neurotrophic factor gene delivery in Parkinson's disease: a delicate balance between neuroprotection, trophic effects, and unwanted compensatory mechanisms. *Front Neuroanat* 11: 1-12. <https://doi.org/10.3389/fnana.2017.00029>
30. Mahato AK, Sidorova YA (2020) Glial cell line-derived neurotrophic factors (GFLs) and small molecules targeting RET receptor for the treatment of pain and Parkinson's disease. *Cell Tissue Res* 382: 147-160. <https://doi.org/10.1007/s00441-020-03227-4>
31. Kumari S, Kamiya A, Karnik SS, Rohilla S, Dubey SK, et al. (2025) Novel gene therapy approaches for targeting neurodegenerative disorders: focusing on delivering neurotrophic genes. *Mol Neurobiol* 62: 386-411. <https://doi.org/10.1007/s12035-024-04260-y>
32. Kelly MJ, O'Keeffe GW, Sullivan AM (2015) Viral vector delivery of neurotrophic factors for Parkinson's disease therapy. *Expert Rev Mol Med* 17: 1-14. <https://doi.org/10.1017/erm.2015.6>
33. Herzog CD, Brown L, Kruegel BR, Wilson A, Tansey MG, et al. (2013) Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120). *Neurobiol Dis* 58: 38-48. <https://doi.org/10.1016/j.nbd.2013.04.011>
34. More SV, Choi DK (2016) Emerging preclinical pharmacological targets for Parkinson's disease. *Oncotarget* 7: 29835-29863. <https://doi.org/10.18632/oncotarget.8104>
35. Valadez-Barba V, Juárez-Navarro K, Padilla-Camberos E, Díaz NF, Guerra-Mora JR, et al. (2023) Parkinson's disease: an update on preclinical studies of induced pluripotent stem cells. *Neurologia (Engl Ed)* 38: 681-694. <https://doi.org/10.1016/j.nrleng.2023.10.004>
36. Galvan A, Devergnas A, Wichmann T (2015) Alterations in neuronal activity in basal ganglia-thalamocortical circuits in the parkinsonian state. *Front Neuroanat* 9: 1-21. <https://doi.org/10.3389/fnana.2015.00005>
37. Bhatia D (2020) A study on basal ganglia circuit and its relation with movement disorders. In *Ontology-Based Information Retrieval for Healthcare Systems*.
38. He Y, Wei Z, Xu J, Jin F, Li T, et al. (2025) Genetics-based targeting strategies for precise neuromodulation. *Adv Sci* 12: e13817. <https://doi.org/10.1002/adv.202413817>
39. Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, Goodspeed K, Gray SJ, et al. (2021) Current clinical applications of *in vivo* gene therapy with AAVs. *Mol Ther* 29: 464-488. <https://doi.org/10.1016/j.ymthe.2020.12.007>
40. Nuss P (2015) Anxiety disorders and GABA neurotransmission: a disturbance of modulation. *Neuropsychiatr Dis Treat* 16: 165-175. <https://doi.org/10.2147/ndt.s58841>
41. Tang X, Huang Z, Zhu G, Liang H, Sun H, et al. (2024) Matching supplementary motor area-primary motor cortex paired transcranial magnetic stimulation improves motor dysfunction in Parkinson's disease: a single-center, double-blind randomized controlled clinical trial protocol. *Front Aging Neurosci* 16: 1-10. <https://doi.org/10.3389/fnagi.2024.1422535>
42. Krishna V, Fishman PS, Eisenberg HM, Kaplitt M, Baltuch G, et al. (2023) Trial of globus pallidus focused ultrasound ablation in Parkinson's disease. *N Engl J Med* 388: 683-693. <https://doi.org/10.1056/nejmoa2202721>
43. Niethammer M, Tang CC, Vo A, Nguyen N, Spetsieris P, et al. (2018) Gene therapy reduces Parkinson's disease symptoms by reorganizing functional brain connectivity. *Sci Transl Med* 10: eaau0713. <https://doi.org/10.1126/scitranslmed.aau0713>
44. Lozano AM, Lipsman N, Bergman H, Brown P, Chabardes S, et al. (2019) Deep brain stimulation: current challenges and future directions. *Nat Rev Neurol* 15: 148-160. <https://doi.org/10.1038/s41582-018-0128-2>
45. Ling Q, Herstine JA, Bradbury A, Gray SJ (2023) AAV-based *in vivo* gene therapy for neurological disorders. *Nat Rev Drug Discov* 22: 789-806. <https://doi.org/10.1038/s41573-023-00766-7>
46. Kumar V (2025) Unlocking the potential of gene therapy: principles and therapeutic applications. In Pathak A, Singh SP (eds) *Next-Generation Drug Delivery Systems. Methods in Pharmacology and Toxicology*. Humana, New York, NY, pp 461-471.
47. Kolesnik VV, Nurtdinov RF, Oloruntimehin ES, Karabelsky AV, Malogolovkin AS



- (2024) Optimization strategies and advances in the research and development of AAV-based gene therapy to deliver large transgenes. *Clin Transl Med* 14: e1607. <https://doi.org/10.1002/ctm2.1607>
48. Styk Ž, Stachowiak N, Małecki M (2024) Recombinant adeno-associated virus vectors for gene therapy of the central nervous system: delivery routes and clinical aspects. *Biomedicines* 12: 1523. <https://doi.org/10.3390/biomedicines12071523>
  49. Egorova T, Starikova A, Polikarpova A (2025) Emerging technologies tackling adeno-associated viruses (AAV) immunogenicity in gene therapy applications. *Pharmaceutics* 17: 1492. <https://doi.org/10.3390/pharmaceutics17111492>
  50. Wang JH, Gessler DJ, Zhan W, Gallagher TL, Gao G (2024) Adeno-associated virus as a delivery vector for gene therapy of human diseases. *Signal Transduct Target Ther* 9: 1-33. <https://doi.org/10.1038/s41392-024-01780-w>
  51. Albert K, Voutilainen MH, Domanskyi A, Airavaara M (2017) AAV vector-mediated gene delivery to substantia nigra dopamine neurons: implications for gene therapy and disease models. *Genes* 8: 63. <https://doi.org/10.3390/genes8020063>
  52. Gray SJ, Foti SB, Schwartz JW, Bachaboina L, Taylor-Blake B, et al. (2011) Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. *Hum Gene Ther* 22: 1143-1153. <https://doi.org/10.1089/hum.2010.245>
  53. Xu X, Holmes TC, Luo MH, Beier KT, Horwitz GD, et al. (2020) Viral vectors for neural circuit mapping and recent advances in trans-synaptic anterograde tracers. *Neuron* 107: 1029-1047. <https://doi.org/10.1016/j.neuron.2020.07.010>
  54. Keravala A, Ormerod BK, Palmer TD, Calos MP (2008) Long-term transgene expression in mouse neural progenitor cells modified with  $\phi$ C31 integrase. *J Neurosci Methods* 173: 299-305. <https://doi.org/10.1016/j.jneumeth.2008.06.005>
  55. Yadav VK, Dhanasekaran S, Choudhary N, Nathiya D, Thakur V, et al. (2025) Recent advances in nanotechnology for Parkinson's disease: diagnosis, treatment, and future perspectives. *Front Med (Lausanne)* 12: 1-26. <https://doi.org/10.3389/fmed.2025.1535682>
  56. Cesana D, Ranzani M, Volpin M, Bartholomae C, Duros C, et al. (2014) Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors *in vivo*. *Mol Ther* 22: 774-785. <https://doi.org/10.1038/mt.2014.3>
  57. Xue W, Fulco C, Sha S, Alden N, Panteli J, et al. (2024) Adeno-associated virus perfusion enhanced expression: a commercially scalable, high titer, high quality producer cell line process. *Mol Ther Methods Clin Dev* 32: 1-13. <https://doi.org/10.1016/j.omtm.2024.101266>
  58. Bulcha JT, Wang Y, Ma H, Tai PW, Gao G (2021) Viral vector platforms within the gene therapy landscape. *Signal Transduct Target Ther* 6: 1-24. <https://doi.org/10.1038/s41392-021-00487-6>
  59. Haggerty DL, Grecco GG, Reeves KC, Atwood B (2020) Adeno-associated viral vectors in neuroscience research. *Mol Ther Methods Clin Dev* 17: 69-82. <https://doi.org/10.1016/j.omtm.2019.11.012>
  60. Mátrai J, Chuah MK, VandenDriessche T (2010) Recent advances in lentiviral vector development and applications. *Mol Ther* 18: 477-490. <https://doi.org/10.1038/mt.2009.319>
  61. Schulz M, Levy DI, Petropoulos CJ, Bashirians G, Winburn I, et al. (2023) Binding and neutralizing anti-AAV antibodies: detection and implications for rAAV-mediated gene therapy. *Mol Ther* 31: 616-630. <https://doi.org/10.1016/j.ymthe.2023.01.010>
  62. Johnson NM, Alvarado AF, Moffatt TN, Edavettal JM, Swaminathan TA, et al. (2021) HIV-based lentiviral vectors: origin and sequence differences. *Mol Ther Methods Clin Dev* 21: 451-465. <https://doi.org/10.1016/j.omtm.2021.03.018>
  63. Ye D, Chukwu C, Yang Y, Hu Z, Chen H (2024) Adeno-associated virus vector delivery to the brain: technology advancements and clinical applications. *Adv Drug Deliv Rev* 211: 115363. <https://doi.org/10.1016/j.addr.2024.115363>
  64. Terstappen GC, Meyer AH, Bell RD, Zhang W (2021) Strategies for delivering therapeutics across the blood-brain barrier. *Nat Rev Drug Discov* 20: 362-383. <https://doi.org/10.1038/s41573-021-00139-y>
  65. Dolgacheva LP, Zinchenko VP, Goncharov NV (2022) Molecular and cellular interactions in pathogenesis of sporadic Parkinson disease. *Int J Mol Sci* 23: 13043. <https://doi.org/10.3390/ijms232113043>
  66. Faraji AH, Rajendran S, Jaquins-Gerstl AS, Hayes HJ, Richardson RM (2021) Convection-enhanced delivery and principles of extracellular transport in the brain. *World Neurosurg* 151: 163-171. <https://doi.org/10.1016/j.wneu.2021.05.050>
  67. Rolfe NW, Dadario NB, Canoll P, Bruce JN (2024) A review of therapeutic agents given by convection-enhanced delivery for adult glioblastoma. *Pharmaceutics (Basel)* 17: 973. <https://doi.org/10.3390/ph17080973>
  68. Tarsy D, Vitek JL, Starr P, Okun M, eds. (2008) *Deep Brain Stimulation in Neurological and Psychiatric Disorders*. Springer Science & Business Media.
  69. Hwu PWL, Kiening K, Anselm I, Compton DR, Nakajima T, et al. (2021) Gene therapy in the putamen for curing AADC deficiency and Parkinson's disease. *EMBO Mol Med* 13: 1-5. <https://doi.org/10.15252/emmm.202114712>
  70. Marshall P (2023) Finding an optimal level of GDNF overexpression: insights from dopamine cycling. *Cell Mol Neurobiol* 43: 3179-3189. <https://doi.org/10.1007/s10571-023-01375-z>
  71. Dücks M, Blazevic D, Rechtsteiner P, Kenny C, Lamla T, et al. (2023) AAV-mediated expression of a new conformational anti-aggregated  $\alpha$ -synuclein antibody prolongs survival in a genetic model of  $\alpha$ -synucleinopathies. *NPJ Parkinsons Dis* 9: 1-15. <https://doi.org/10.1038/s41531-023-00542-9>
  72. Fajardo-Serrano A, Rico AJ, Roda E, Honrubia A, Arrieta S, et al. (2021) Adeno-associated viral vectors as versatile tools for Parkinson's research, both for disease modeling purposes and for therapeutic uses. *Int J Mol Sci* 22: 6389. <https://doi.org/10.3390/ijms22126389>
  73. Safety Committee of Japanese Society of Anesthesiologists (2020) Practical guide for safe central venous catheterization and management 2017. *J Anesth* 34: 167-186. <https://doi.org/10.1007/s00540-019-02702-9>
  74. Bankiewicz K (2013) *Neurosurgical Approaches: Drug Infusion Directly into the Parenchyma or the Cerebrospinal Fluid*. In Hammarlund-Udenaes M, de Lange E, Thorne R (eds) *Drug Delivery to the Brain: Physiological Concepts, Methodologies and Approaches*. Springer, New York, pp 501-518.
  75. Rocco MT, Akhter AS, Ehrlich DJ, Scott GC, Lungu C, et al. (2022) Long-term safety of MRI-guided administration of AAV2-GDNF and gadoteridol in the putamen of individuals with Parkinson's disease. *Mol Ther* 31: 2296. <https://doi.org/10.1016/j.ymthe.2023.04.009>
  76. Christine CW, Bankiewicz KS, Van Laar AD, Richardson RM, Ravina B, et al. (2019) Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease. *Ann Neurol* 85: 704-714. <https://doi.org/10.1002/ana.25450>
  77. Onuki Y, Ono S, Nakajima T, Kojima K, Taga N, et al. (2021) Dopaminergic restoration of prefrontal cortico-putaminal network in gene therapy for aromatic l-amino acid decarboxylase deficiency. *Brain Commun* 3: 1-14. <https://doi.org/10.1093/braincomms/fcab078>
  78. Savulescu J, Wartolowska K, Carr A (2016) Randomised placebo-controlled trials of surgery: ethical analysis and guidelines. *J Med Ethics* 42: 776-783. <https://doi.org/10.1136/medethics-2015-103333>
  79. Ciccozzi M, Menga R, Ricci G, Vitali MA, Angeletti S, et al. (2016) Critical review of sham surgery clinical trials: confounding factors analysis. *Ann Med Surg* 12: 21-26. <https://doi.org/10.1016/j.amsu.2016.10.007>
  80. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease (2003) The unified Parkinson's disease rating scale (UPDRS): status and recommendations. *Mov Disord* 18: 738-750. <https://doi.org/10.1002/mds.10473>
  81. Koschel J, Ray Chaudhuri K, Tönges L, Thiel M, Raeder V, et al. (2022) Implications of dopaminergic medication withdrawal in Parkinson's disease. *J Neural Transm (Vienna)* 129: 1169-1178. <https://doi.org/10.1007/s00702-021-02389-x>
  82. Subert M, Tykalova T, Novotny M, Bezdicek O, Dusek P, et al. (2025) Long-term dopaminergic therapy improves spoken language in de novo Parkinson's disease. *J Neurol* 272: 1-11. <https://doi.org/10.1007/s00415-025-13070-8>
  83. Matarazzo M, Perez-Soriano A, Stoessl AJ (2018) Dyskinesias and levodopa therapy: why wait? *J Neural Transm (Vienna)* 125: 1119-1130. <https://doi.org/10.1007/s00702-018-1856-6>
  84. Mischley LK, Lau RC, Weiss NS (2017) Use of a self-rating scale of the nature and severity of symptoms in Parkinson's disease (PRO-PD): correlation with quality of life and existing scales of disease severity. *NPJ Parkinsons Dis* 3: 1-7. <https://doi.org/10.1038/s41531-017-0021-5>
  85. Kelly KM, Borstad AL, Kline D, Gauthier LV (2018) Improved quality of life following constraint-induced movement therapy is associated with gains in arm use, but not motor improvement. *Top Stroke Rehabil* 25: 467-474. <https://doi.org/10.1080/10749357.2018.1481605>
  86. Kieburz K, Katz R, McGarry A, Olanow CW (2021) A new approach to the development of disease-modifying therapies for PD; fighting another pandemic. *Mov Disord* 36: 59-63. <https://doi.org/10.1002/mds.28310>





87. Kim TY, Lee BD (2025) Current therapeutic strategies in Parkinson's disease: future perspectives. *Mol Cells* 48: 100274. <https://doi.org/10.1016/j.mocell.2025.100274>
88. Ikeda K, Ebina J, Kawabe K, Iwasaki Y (2019) Dopamine transporter imaging in Parkinson disease: progressive changes and therapeutic modification after anti-parkinsonian medications. *Intern Med* 58: 1665-1672. <https://doi.org/10.2169/internalmedicine.2489-18>
89. Hafeez M, Eoff E, Wei J, Azhar G (2024) Missed insights for earlier management of Parkinson's disease and the value of dopamine transporter (DAT) scans. *Geriatrics* 9: 126. <https://doi.org/10.3390/geriatrics9050126>
90. Venuto CS, Potter NB, Ray Dorsey E, Kieburz K (2016) A review of disease progression models of Parkinson's disease and applications in clinical trials. *Mov Disord* 31: 947-956. <https://doi.org/10.1002/mds.26644>
91. Schreiner TG, Menéndez-González M, Schreiner OD, Ciobanu RC (2025) Intrathecal therapies for neurodegenerative diseases: a review of current approaches and the urgent need for advanced delivery systems. *Biomedicines* 13: 2167. <https://doi.org/10.3390/biomedicines13092167>
92. Vargason AM, Anselmo AC, Mitragotri S (2021) The evolution of commercial drug delivery technologies. *Nat Biomed Eng* 5: 951-967. <https://doi.org/10.1038/s41551-021-00698-w>
93. Wang D, Tai PW, Gao G (2019) Adeno-associated virus vector as a platform for gene therapy delivery. *Nat Rev Drug Discov* 18: 358-378. <https://doi.org/10.1038/s41573-019-0012-9>
94. Malone H, Yang J, Hershman DL, Wright JD, Bruce JN, et al. (2015) Complications following stereotactic needle biopsy of intracranial tumors. *World Neurosurg* 84: 1084-1089. <https://doi.org/10.1016/j.wneu.2015.05.025>
95. Hamilton BA, Wright JF (2021) Challenges posed by immune responses to AAV vectors: addressing root causes. *Front Immunol* 12: 1-8. <https://doi.org/10.3389/fimmu.2021.675897>
96. Keeler AM, Zhan W, Ram S, Fitzgerald KA, Gao G (2025) The curious case of AAV immunology. *Mol Ther* 33: 1946-1965. <https://doi.org/10.1016/j.ymthe.2025.03.037>
97. Arjomandnejad M, Dasgupta I, Flotte TR, Keeler AM (2023) Immunogenicity of recombinant adeno-associated virus (AAV) vectors for gene transfer. *BioDrugs* 37: 311-329. <https://doi.org/10.1007/s40259-023-00585-7>
98. Chi H, Pepper M, Thomas PG (2024) Principles and therapeutic applications of adaptive immunity. *Cell* 187: 2052-2078. <https://doi.org/10.1016/j.cell.2024.03.037>
99. Harkins AL, Ambegaokar PP, Keeler AM (2024) Immune responses to central nervous system directed adeno-associated virus gene therapy: does direct CNS delivery make a difference? *Neurotherapeutics* 21: 1-11. <https://doi.org/10.1016/j.neurot.2024.e00435>
100. Fischell JM, Fishman PS (2021) A multifaceted approach to optimizing AAV delivery to the brain for the treatment of neurodegenerative diseases. *Front Neurosci* 15: 1-20. <https://doi.org/10.3389/fnins.2021.747726>
101. Kantor B, O'Donovan B, Chiba-Falek O (2025) Trends and challenges of AAV-delivered gene editing therapeutics for unmet needs in CNS disorders: implications for neurodegenerative disease. *Mol Ther Nucleic Acids* 36: 1-21. <https://doi.org/10.1016/j.omtn.2025.102635>
102. Jaballah SA, Ali LM, Jihad MA, Akhlaq S, Rizvi TA, et al. (2025) Retroviral vector technology for gene therapy: history, current landscape, and future prospects. *J Mol Biol*: 169473. <https://doi.org/10.1016/j.jmb.2025.169473>
103. Kohn DB, Booth C, Shaw KL, Xu-Bayford J, Garabedian E, et al. (2021) Autologous ex vivo lentiviral gene therapy for adenosine deaminase deficiency. *N Engl J Med* 384: 2002-2013. <https://doi.org/10.1056/nejmoa2027675>
104. Morris HR, Spillantini MG, Sue CM, Williams-Gray CH (2024) The pathogenesis of Parkinson's disease. *Lancet* 403: 293-304. [https://doi.org/10.1016/S0140-6736\(23\)01478-2](https://doi.org/10.1016/S0140-6736(23)01478-2)
105. Buttery PC, Barker RA (2020) Gene and cell-based therapies for Parkinson's disease: where are we? *Neurotherapeutics* 17: 1539-1562. <https://doi.org/10.1007/s13311-020-00940-4>